Inclusion Criteria:  Age greater than or equal to18 years old, male or female; Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 1; Life expectancy >12 weeks; Histologically or cytologically confirmed B cell lymphoma; Relapsed and/or refractory disease after at least 1 prior treatment regimen; At least one measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or one measurable extra nodal lesion, defined as > 1.0 cm in its longest diameter (no need for dose escalation stage).  Exclusion Criteria:  Received autologous stem cell transplantation within 12 weeks before the first study treatment; previously received allogeneic stem cell transplantation or Car-T cell therapy; History of recent major surgery or severe trauma within 4 weeks before the first study treatment; Received anti-tumour treatment within 2 weeks before the first study treatment; Central nervous system (CNS) infiltration; Active infection with HBV or HCV; History of immunodeficiency, including HIV serotest positive, or other acquired or congenital immunodeficiency diseases, and active tuberculosis; Active infection or unexplained fever>38.5℃; History of severe cardiovascular disease.